How did GLYC's revenue and expenses shift in Q4 2024?
5/8/2025 02:11pm
Aime
Glycomimetics (GLYC) experienced a significant shift in its financial metrics during Q4 2024, with total revenue decreasing, while cost of goods sold, R&D expenses, and sales and marketing expenses increased compared to the previous quarter1:
GLYC R&D Expenses
Source:
1.
GLYC Revenue, Cost of Sales, R&D Expenses, Sales and Marketing Expenses, Financial Expenses in Q4 2024
more
less
Explore
Screener
Best looking stocks that are MACD Golden Cross
Analysis
What is the trend of APOG's stock price?
Learn
What is a smart contract and give examples
Wiki
For diabetes, what foods or drink are good to consume?